Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24609799 | 0.94 | MEN1 (0.47) | MEN1KMT2AKCNMA1SERPINE1KDM4E | |
| SCHEMBL24609775 | 0.94 | MEN1 (0.52) | MEN1KMT2AKCNMA1SERPINE1KDM4E | |
| SCHEMBL24609685 | 0.92 | SERPINE1 (0.48) | MEN1KMT2AKCNMA1SERPINE1KDM4E | |
| SCHEMBL22912465 | 0.88 | SERPINE1 (0.46) | MEN1KMT2AKCNMA1SERPINE1KDM4E | |
| SCHEMBL24610035 | 0.86 | MEN1 (0.53) | MEN1KMT2AKCNMA1SERPINE1KDM4E | |
| SCHEMBL24609678 | 0.85 | SERPINE1 (0.48) | MEN1KMT2AKCNMA1SERPINE1KDM4E | |
| SCHEMBL24609656 | 0.85 | SERPINE1 (0.53) | MEN1KMT2AKCNMA1SERPINE1KDM4E | |
| SCHEMBL24609895 | 0.80 | SERPINE1 (0.48) | MEN1KMT2AKCNMA1SERPINE1KDM4E | |
| SCHEMBL24609579 | 0.78 | SERPINE1 (0.54) | MEN1KMT2AKCNMA1SERPINE1KDM4E | |
| SCHEMBL21030832 | 0.77 | KCNMA1 (0.68) | MEN1KMT2AKCNMA1SERPINE1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213098-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213098-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | CRY1, CYP1A1, CYP1B1 | MEN1 343/4885KMT2A 794/4885KCNMA1 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.